Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to Acceptance of a Subsidiary's Drug Registration Application" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
6 July 2023

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Stock code： 600196　　Stock abbreviation： Fosun Pharma　　No.: Lin 2023-081

Bond code： 143422　　Bond abbreviation： 18 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission and accept legal liability for the truthfulness, accuracy and completeness of the contents contained herein.

I. Overview

Recently, the drug registration application of RT002 (DaxibotulinumtoxinA , the "**New Drug**") which has been licensed to Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) ("**Fosun Pharmaceutical Industrial**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**" and, together with its subsidiaries/units, the "**Group**", the same applies below), which is indicated for the treatment of cervical dystonia in adults, was accepted by the National Medical Products Administration ("**NMPA**").

II. Basic information and Research Progress of the New Drug

Fosun Pharmaceutical Industrial was granted the authorization in December 2018, in relation to the rights to use, import, sales and other commercial activities (excluding manufacturing) of the New Drug in the Region (i.e. Mainland China, Hong Kong and Macau Special Administrative Regions, hereinafter the same) on an exclusive basis by Revance Therapeutics, Inc. ("**Revance**") which is based in the U.S.. Revance is still the owner of the New Drug in the Region. The New Drug is a

biological product which is intended for (1) aesthetic indications such as improvement of moderate to severe glabellar lines in adults; and (2) treatment of indications such as cervical dystonia in adults.

The New Drug is used for the improvement of moderate to severe glabellar lines in adults and has been approved for market launch by the FDA (namely the U.S. Food and Drug Administration) in September 2022. The registration application of the New Drug which is used for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults has been accepted by the NMPA in April 2023. As at the date of this announcement, the application of the New Drug which is used for the treatment of cervical dystonia in adults is currently under FDA regulatory review.

As at the date of this announcement, no Botulinum Toxin product of Type Daxibotulinumtoxin A was launched for sale in China (hereinafter excluding Hong Kong, Macau and Taiwan region for the purpose of this announcement, the same applies below). Products of Botulinum Toxin Type A for Injection that have already been launched in China include Botox® (保妥适®) of AbbVie Limited, HENGLI (衡力®) of Lanzhou Biotechnique Development Co., Ltd.* (蘭州生物技術開發有限公司) , Letybo® (乐提葆®) of Hugel, Inc., and Dysport® (吉适®) of Ipsen Limited. According to the latest data from IQVIA CHPA (provided by IQVIA, a professional information and strategic consulting service provider for the pharmaceutical and health industry; IQVIA CHPA data represents the drug sales market of hospitals with over 100 beds in China .The actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales distribution channels), the sales of Botulinum Toxin Type A for Injection in China in 2022 amounted to approximately RMB557 million.

As of May 2023, the Group has invested approximately RMB337.08 million (unaudited; including license fee) in total in the research and development of the New Drug at this stage.

III. Risk Warning

The New Drug is subject to, among others, the obtainment of drug registration approval before it can be commercialized in China. This acceptance of the drug registration application is not expected to have a material impact on the current results of the Group.

Due to the characteristics of the pharmaceutical products industry, the specific sales performance of the pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

6 July 2023

*For identification purposes only